Executive Vice President Chief Medical Officer
Dr. Michael Rosenblatt, M.D., is Executive Vice President, Chief Medical Officer of Merck Co., Inc. He is responsible for the Companys primary voice to the global medical community on critical issues such as patient safety and oversight for the Companys Global Center for Scientific Affairs. Prior to December 2009, Dr. Rosenblatt was the Dean of Tufts University School of Medicine since 2003.
Age: 67 President Since 2009 Ph.D
908 735-1500 www.merck.com
The company has Return on Asset of 0.06 %
which means that on every $100 spent on asset it made $0.06 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE)
of 6.9 %
implying that it generated $6.9 on every 100 dollars invested.
The company has 26.41 B in debt with debt to equity (D/E) ratio of 0.57 which is OK given its current industry classification. Merck Co Inc has Current Ratio of 1.85 which is typical for the industry and considered as normal.
Merck & Co., Inc. offer healthcare solutions worldwide. Merck Co Inc (MRK) is traded on New York Stock Exchange in USA. It is located in NEW JERSEY, U.S.A and employs 66,645 people. Merck is listed under Pharmaceutical Products category by Fama And French industry classification and specializes in Healthcare
with concentration in Pharmaceuticals And Biosciences